AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31630532 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive early rehabilitation for four weeks
Number of subjects: 0
Study 31630532 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 31630532 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational consultations
Number of subjects: 0
Study 31630532 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital exercise training
Number of subjects: 0
Study 31630532 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge exercise training
Number of subjects: 0
Study 30433862 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg oral BH4 (BH4-5)
Number of subjects: 29
Study 30433862 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg oral BH4 (BH4-20)
Number of subjects: 29
Study 30433862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 29
Study 28787518 — intervention group
Group type: EXPERIMENTAL
Intervention: Visian Implantable Collamer Lens (ICL) implantation in the ciliary sulcus
Number of subjects: 18
Study 26438119 — intervention group
Group type: EXPERIMENTAL
Intervention: mDCF (fluorouracil 2,000 mg/m2 IV over 48 hours, docetaxel 40 mg/m2 IV on day 1, cisplatin 40 mg/m2 IV on day 3, every 2 weeks)
Number of subjects: 85
Study 26438119 — intervention group
Group type: COMPARATOR
Intervention: DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2, and fluorouracil 750 mg/m2 IV over 5 days with granulocyte colony‐stimulating factor, every 3 weeks)
Number of subjects: 85
Study 24821270 — intervention group
Group type: EXPERIMENTAL
Intervention: MI + education
Number of subjects: 350
Study 24821270 — intervention group
Group type: COMPARATOR
Intervention: education alone
Number of subjects: 350
Study 23039034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r) 40/10 mg twice daily if 2-4 kg and 80/20 mg twice daily if >4 kg
Number of subjects: 1500
Study 23039034 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 7.5 mg twice daily if 2-4 kg, 25 mg twice daily if 4-8 kg and 50 mg twice daily if >8 kg
Number of subjects: 1500
Study 19874149 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Function Index ‐ VF‐14
Number of subjects: 1160
Study 19874149 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment, self‐reported poor vision, dependence in daily activities, cognitive impairment, depressive symptoms, female gender, older age
Number of subjects: 1160
Study 19874149 — intervention group
Group type: EXPERIMENTAL
Intervention: VA of less than 6/18 in the better eye
Number of subjects: 1160
Study 19874149 — intervention group
Group type: EXPERIMENTAL
Intervention: VA of less than 6/12
Number of subjects: 1160
Study 17700042 — intervention group
Group type: EXPERIMENTAL
Intervention: S 17092 (100, 200, 400 or 600 mg)
Number of subjects: 48
Study 17700042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15516262 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) photocoagulation
Number of subjects: 30
Study 15516262 — intervention group
Group type: COMPARATOR
Intervention: Argon green laser (514 nm)
Number of subjects: 30
Study 11192866 — intervention group
Group type: EXPERIMENTAL
Intervention: Azodicarbonamide (ADA)
Number of subjects: 15
Study 11192866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9452280 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: Berlin-Frankfurt-Munster (BFM) 76/79
Number of subjects: 694
Study 9452280 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: LSA2-L2 with cranial irradiation
Number of subjects: 694
Study 9452280 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: LSA2-L2 without cranial irradiation
Number of subjects: 694
Study 9452280 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen D: New York (NY) regimen
Number of subjects: 694
Study 9452280 — intervention group
Group type: COMPARATOR
Intervention: Historic group
Number of subjects: 694
Study 8747561 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 35 micrograms/kg during atracurium block
Number of subjects: 45
Study 8747561 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 35 micrograms/kg during vecuronium block
Number of subjects: 45
Study 8747561 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 70 micrograms/kg during atracurium block
Number of subjects: 45
Study 2677956 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 105
Study 2677956 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone
Number of subjects: 105
Study 406561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin therapy
Number of subjects: 45
Study 406561 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin therapy
Number of subjects: 45
Study 406561 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular insulin therapy
Number of subjects: 45
Study 30443924 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence to HTN treatment
Number of subjects: 2362
Study 30443924 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor adherence to HTN treatment
Number of subjects: 2362
Study 30443924 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence
Number of subjects: 2362
Study 26933140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile device (iPad)
Number of subjects: 60
Study 26933140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile device (iTouch)
Number of subjects: 60
Study 26933140 — intervention group
Group type: COMPARATOR
Intervention: Traditional test platform
Number of subjects: 60
Study 26933140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficients
Number of subjects: 60
Study 25821405 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 μg/kg administered 30 seconds before induction
Number of subjects: 151
Study 25821405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remifentanil)
Number of subjects: 151
Study 25821405 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil group
Number of subjects: 151
Study 25821405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 151
Study 23445184 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-mediated medication management
Number of subjects: 91
Study 23445184 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver characteristics (age, cognitive ability, depressive symptoms)
Number of subjects: 91
Study 21388549 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral rosuvastatin administered once daily for 14 days
Number of subjects: 80
Study 21388549 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo administered once daily for 14 days
Number of subjects: 80
Study 19270824 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with capecitabine and cisplatin
Number of subjects: 18
Study 17355494 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioctic acid 600 mg p.o./day
Number of subjects: 54
Study 17355494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15121727 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg i.v.
Number of subjects: 36
Study 15121727 — intervention group
Group type: COMPARATOR
Intervention: ketorolac 30 mg i.v.
Number of subjects: 36
Study 11402509 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions only
Number of subjects: 37
Study 11402509 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions with a 5s stretch
Number of subjects: 37
Study 9734679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin
Number of subjects: 375
Study 9734679 — intervention group
Group type: COMPARATOR
Intervention: Parenteral gold
Number of subjects: 375
Study 9277060 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative Prenatal Care Visit Schedule (APCVS) (n = 43)
Number of subjects: 81
Study 9277060 — intervention group
Group type: COMPARATOR
Intervention: Traditional Prenatal Care Visit Schedule (TPCVS) (n = 38)
Number of subjects: 81
Study 1820894 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg)
Number of subjects: 8
Study 6294699 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal octapeptide of cholecystokinin (CCK-8, 4 ng . kg‐1 . min‐1)
Number of subjects: 8
Study 6294699 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 30654453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HYPO) and exercise (5 days/week, 80⁻85% HRmax)
Number of subjects: 16
Study 30654453 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric diet (EU) and exercise (5 days/week, 80⁻85% HRmax)
Number of subjects: 16
Study 30654453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HYPO)
Number of subjects: 16
Study 28849796 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step universal adhesive (All-Bond Universal: AU)
Number of subjects: 57
Study 28849796 — intervention group
Group type: COMPARATOR
Intervention: 2-step self-etch adhesive (Optibond XTR: OX)
Number of subjects: 57
Study 26607392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (800 μg/day for 16 weeks)
Number of subjects: 62
Study 24882698 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Sxscore high tertile (≥19)
Number of subjects: 1132
Study 24882698 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Sxscore intermediate tertile (11-18)
Number of subjects: 1132
Study 24882698 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Sxscore low tertile (≤10)
Number of subjects: 1132
Study 24882698 — intervention group
Group type: COMPARATOR
Intervention: BMS (bare-metal stents)
Number of subjects: 1132
Study 24882698 — intervention group
Group type: COMPARATOR
Intervention: BES (biolimus-eluting stents)
Number of subjects: 1132
Study 22294059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine administered in the fasted state
Number of subjects: 0
Study 22294059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine administered 15 min before a standard breakfast
Number of subjects: 0
Study 22294059 — intervention group
Group type: COMPARATOR
Intervention: Lercanidipine taken immediately after a carbohydrate-rich meal
Number of subjects: 0
Study 21120303 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental stabilization
Number of subjects: 30
Study 21120303 — intervention group
Group type: COMPARATOR
Intervention: Superficial strengthening
Number of subjects: 30
Study 18507563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing educational intervention (brief education and counselling)
Number of subjects: 3522
Study 15934121 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise program
Number of subjects: 277
Study 15934121 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 277
Study 12652460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus FCM (fludarabine/cyclophosphamide/mitoxantrone)
Number of subjects: 94
Study 12652460 — intervention group
Group type: COMPARATOR
Intervention: FCM alone
Number of subjects: 94
Study 12652460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus FCM in follicular lymphoma
Number of subjects: 94
Study 12652460 — intervention group
Group type: COMPARATOR
Intervention: FCM alone in follicular lymphoma
Number of subjects: 94
Study 12652460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus FCM in mantle cell lymphoma
Number of subjects: 94
Study 12652460 — intervention group
Group type: COMPARATOR
Intervention: FCM alone in mantle cell lymphoma
Number of subjects: 94
Study 12652460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus FCM
Number of subjects: 94
Study 10587334 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of lisinopril (32.5 to 35 mg daily)
Number of subjects: 3164
Study 10587334 — intervention group
Group type: COMPARATOR
Intervention: Low doses of lisinopril (2.5 to 5.0 mg daily)
Number of subjects: 3164
Study 9193426 — intervention group
Group type: EXPERIMENTAL
Intervention: High ACE activity (> 12 IU/L)
Number of subjects: 102
Study 9193426 — intervention group
Group type: COMPARATOR
Intervention: Low ACE activity (<= IU/L)
Number of subjects: 102
Study 1554040 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone suppository treatment
Number of subjects: 129
Study 1554040 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (placebo-controlled)
Number of subjects: 129
Study 2861874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pipothiazine palmitate (PP)
Number of subjects: 30
Study 2861874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30592635 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 167
Study 30592635 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone with PT and psychostimulant
Number of subjects: 167
Study 30592635 — intervention group
Group type: COMPARATOR
Intervention: Placebo with PT and psychostimulant
Number of subjects: 167
Study 29077654 — intervention group
Group type: EXPERIMENTAL
Intervention: NFAT-regulated gene expression monitoring
Number of subjects: 55
Study 29077654 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacokinetic monitoring by cyclosporine trough levels
Number of subjects: 55
Study 27598730 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive Keratectomy (PRK)
Number of subjects: 74
Study 27598730 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Incision Lenticule Extraction (SMILE)
Number of subjects: 74
Study 24764147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Pantoprazole
Number of subjects: 24
Study 24764147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Rabeprazole
Number of subjects: 24
Study 24764147 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 24
Study 22985140 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multicomponent physical activity counseling (PAC) intervention
Number of subjects: 302
Study 22985140 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 302
Study 19413520 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI screening in women with inherited mutations
Number of subjects: 0
Study 19413520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography in asymptomatic women with dense breasts
Number of subjects: 0
Study 19413520 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD)
Number of subjects: 0
Study 17307440 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary muscle repositioning (PMR group)
Number of subjects: 100
Study 17307440 — intervention group
Group type: COMPARATOR
Intervention: Complete preservation of all chordal structures with mitral valve replacement (CMVR group)
Number of subjects: 100
Study 15144393 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA 5 J/cm(2)
Number of subjects: 78
Study 15144393 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA 10 J/cm(2)
Number of subjects: 78
Study 15144393 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA 20 J/cm(2)
Number of subjects: 78
Study 11278152 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated schizophrenic patients during initial assessment after receiving medication
Number of subjects: 56
Study 11278152 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated schizophrenic patients after sustained treatment
Number of subjects: 56
Study 11278152 — intervention group
Group type: COMPARATOR
Intervention: First-episode schizophrenic patients (medication-naïve or not)
Number of subjects: 56
Study 8301625 — intervention group
Group type: EXPERIMENTAL
Intervention: Belladonna 30C
Number of subjects: 47
Study 8301625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3595576 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% halothane
Number of subjects: 22
Study 3595576 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% enflurane
Number of subjects: 22
Study 30149417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once a day for 12 weeks
Number of subjects: 24
Study 30037778 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5-10 mg daily
Number of subjects: 81
Study 30037778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 26540028 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/d) for 12 months
Number of subjects: 150
Study 26540028 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 150
Study 26540028 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib-induced skin rash
Number of subjects: 150
Study 26540028 — intervention group
Group type: EXPERIMENTAL
Intervention: LOH-positive patients
Number of subjects: 150
Study 25682903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity lifestyle intervention program
Number of subjects: 213
Study 23774582 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 d · wk(‐1) of aerobic training and 2 d · wk(‐1) resistance training (2 + 2)
Number of subjects: 72
Study 23774582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 d · wk(‐1) of aerobic training and 1 d · wk(‐1) of resistance training (1 + 1)
Number of subjects: 72
Study 23774582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 d · wk(‐1) of aerobic training and 3 d · wk(‐1) of resistance training (3 + 3)
Number of subjects: 72
Study 23774582 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1 + 1, 2 + 2, 3 + 3)
Number of subjects: 72
Study 21051191 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Constraint‐Induced Movement Therapy followed by Bimanual Training (mCIMT‐BiT)
Number of subjects: 52
Study 21051191 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 52
Study 18484473 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam plus amikacin (PTA)
Number of subjects: 87
Study 18484473 — intervention group
Group type: COMPARATOR
Intervention: Carbapenem monotherapy (imipenem or meropenem)
Number of subjects: 87
Study 17139586 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting insulin analogs
Number of subjects: 0
Study 17139586 — intervention group
Group type: COMPARATOR
Intervention: Meta-analyses of short-acting insulin analogs
Number of subjects: 0
Study 17139586 — intervention group
Group type: COMPARATOR
Intervention: Cochrane Review 2005
Number of subjects: 0
Study 17139586 — intervention group
Group type: COMPARATOR
Intervention: Recommendations from IQWiG
Number of subjects: 0
Study 12538750 — intervention group
Group type: EXPERIMENTAL
Intervention: New comorbidity indices developed in the modeling set
Number of subjects: 1041
Study 12538750 — intervention group
Group type: COMPARATOR
Intervention: Existing comorbidity indices (Khan, Davies, Charlson)
Number of subjects: 1041
Study 12538750 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual comorbidities
Number of subjects: 1041
Study 11783322 — intervention group
Group type: EXPERIMENTAL
Intervention: Longshoudan (LSD) treatment for 4 weeks
Number of subjects: 40
Study 11783322 — intervention group
Group type: COMPARATOR
Intervention: Routinely treated ACI patients
Number of subjects: 40
Study 11783322 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 40
Study 9355424 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning
Number of subjects: 0
Study 1489125 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571
Number of subjects: 12
Study 1489125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3479839 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug period
Number of subjects: 0
Study 3479839 — intervention group
Group type: COMPARATOR
Intervention: Placebo period
Number of subjects: 0
Study 3479839 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip prosthesis
Number of subjects: 0
Study 3479839 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (NSAID) or analgesic trials
Number of subjects: 0
Study 31857431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (110 mg/m2) with Irinotecan (90 mg/m2)
Number of subjects: 37
Study 31857431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (85 mg/m2) with Irinotecan (90 mg/m2)
Number of subjects: 37
Study 31857431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (not specified) with Irinotecan (not specified)
Number of subjects: 37
Study 30544376 — intervention group
Group type: EXPERIMENTAL
Intervention: ETView double-lumen tube (VDT)
Number of subjects: 83
Study 30544376 — intervention group
Group type: EXPERIMENTAL
Intervention: ETView single-lumen tube (VST)
Number of subjects: 83
Study 30544376 — intervention group
Group type: COMPARATOR
Intervention: Traditional double lumen tube (DT)
Number of subjects: 83
Study 30544376 — intervention group
Group type: EXPERIMENTAL
Intervention: ETView tubes (VDT/VST)
Number of subjects: 83
Study 30544376 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative outcomes
Number of subjects: 83
Study 30544376 — intervention group
Group type: EXPERIMENTAL
Intervention: ETView single lumen endotracheal tube
Number of subjects: 83
Study 26841085 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200 or 2000 IU/day)
Number of subjects: 167
Study 26841085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 25796155 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengjie Tongyu granules
Number of subjects: 0
Study 25796155 — intervention group
Group type: COMPARATOR
Intervention: Tongxinluo capsule (control)
Number of subjects: 0
Study 23782950 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 μg once daily for 24 to 30 months)
Number of subjects: 492
Study 23782950 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with anti‐thyroid drugs
Number of subjects: 492
Study 23782950 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 492
Study 21112881 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene ropivacaine 0.2% 2 ml h⁻¹ with mandatory 6 hourly boluses
Number of subjects: 81
Study 21112881 — intervention group
Group type: COMPARATOR
Intervention: Continuous interscalene ropivacaine 0.2% 5 ml h⁻¹ with PRN boluses
Number of subjects: 81
Study 19026248 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 12.5 mg
Number of subjects: 525